- Home
- BEAT vs INMB Comparison
BEAT vs INMB Comparison
Compare BEAT & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- INMB
- Stock Information
- Founded
- BEAT 2015
- INMB 2015
- Country
- BEAT United States
- INMB United States
- Employees
- BEAT N/A
- INMB N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- BEAT Technology
- INMB Health Care
- Exchange
- BEAT Nasdaq
- INMB Nasdaq
- Market Cap
- BEAT 57.6M
- INMB 49.2M
- IPO Year
- BEAT 2021
- INMB 2019
- Fundamental
- Price
- BEAT $1.63
- INMB $1.90
- Analyst Decision
- BEAT Buy
- INMB Hold
- Analyst Count
- BEAT 1
- INMB 3
- Target Price
- BEAT $8.00
- INMB $4.30
- AVG Volume (30 Days)
- BEAT 73.9K
- INMB 357.4K
- Earning Date
- BEAT 11-07-2025
- INMB 10-30-2025
- Dividend Yield
- BEAT N/A
- INMB N/A
- EPS Growth
- BEAT N/A
- INMB N/A
- EPS
- BEAT N/A
- INMB N/A
- Revenue
- BEAT N/A
- INMB $50,000.00
- Revenue This Year
- BEAT N/A
- INMB $264.29
- Revenue Next Year
- BEAT $19.35
- INMB $9,819.61
- P/E Ratio
- BEAT N/A
- INMB N/A
- Revenue Growth
- BEAT N/A
- INMB N/A
- 52 Week Low
- BEAT $0.91
- INMB $1.71
- 52 Week High
- BEAT $3.48
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- BEAT 49.06
- INMB 47.06
- Support Level
- BEAT $1.53
- INMB $1.75
- Resistance Level
- BEAT $1.81
- INMB $1.95
- Average True Range (ATR)
- BEAT 0.12
- INMB 0.10
- MACD
- BEAT -0.03
- INMB 0.00
- Stochastic Oscillator
- BEAT 25.00
- INMB 47.24
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.